Loading…
Biotech developing apitegromab, a muscle-growth-promoting myostatin inhibitor for spinal muscular atrophy and other conditions.
Biotech developing apitegromab, a muscle-growth-promoting myostatin inhibitor for spinal muscular atrophy and other conditions.
Has no approved product yet, so it is funded by money raised from investors rather than sales. Any future income would come from selling apitegromab as an add-on to existing spinal muscular atrophy treatments, which work on the nerve cells while apitegromab targets muscle.
Moat: narrow (IP / patents). A selective myostatin-pathway inhibitor differentiated by targeting muscle growth alongside SMA gene therapies.
Headquarters: Cambridge, Massachusetts, US · Founded: 2012 · Employees: 289
Size Scholar Rock (SRRK) is a United States Health Care company (Biotechnology) with a market value of $5.72B, the 1097th largest of 3,117 United States companies the cockpit tracks. Shares closed at $46.94 on 6 Nov 2026.
Performance Over six months the shares fell 3.0%, against +2.4% for the median peer and -1.1% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.
Short interest Short interest is 18.2% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $33.2M |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | -$1.48M | -$1.66M | -$1.94M | -$2.84M | $23.3M |
| EBITDA | -$405M | -$383M | -$250M | -$168M | -$124M |
| Net income | -$409M | -$378M | -$246M | -$166M | -$135M |
| Free cash flow | -$297M | -$301M | -$201M | -$145M | -$134M |
| Capital expenditure | $185,000 | $602,000 | $98,000 | $71,000 | $1.06M |
| Total debt | $204M | $109M | $65.1M | $61.8M | $69.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Scholar Rock SRRK | $5.72B | -3% | n/a | n/a | n/a | n/a |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 6.3× | 1.7% |
| Roche RO.SW | $385B | +22% | -1% | 31% | 5.6× | 0.9% |
| Biogen BIIB | $36.7B | +28% | +2% | 17% | 4.4× | 9.4% |
| Biohaven BHVN | $2.19B | +47% | n/a | n/a | n/a | n/a |
| Regeneron Pharmaceuticals REGN | $93.5B | +27% | +19% | 30% | 5.2× | -2.2% |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 15.2× | 5.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SRRK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.2% | +0.1% | 3rd highest of 21 |
| 6-month return | -3.0% | +2.4% | 8th lowest of 21 |
| Distance from 52-week high | -24.0% | -30.0% | 8th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $5.65B | -1% | +22% | 10% | 5.6× | 28.3% | +15.6% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 24.9× | 36.7% | +26.2% |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.35B | -2% | -28% | -210% | 5.4× | -6.4% | -10.0% |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.92B | -34% | +102% | 61% | 1.2× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.89B | +28% | n/a | n/a | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.89B | -11% | -22% | 17% | 5.7× | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | 133.6× | n/a | n/a |
| CG Oncology CGON | United States | $6.74B | +9% | +1,030% | -4,056% | 917.8× | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.81B | -1% | -61% | -11,441% | 2,087.9× | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.72B | -37% | +8% | -35% | 14.5× | n/a | n/a |
| Axsome Therapeutics AXSM | United States | $6.96B | -39% | +54% | -19% | 7.9× | n/a | n/a |
| Caris Life Sciences CAI | United States | $7.13B | +56% | +85% | 15% | 6.9× | 18.7% | +85.4% |
| Joinn Laboratories (China) 603127.SS | China | $4.58B | +15% | +12% | -4% | 15.1× | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.51B | -13% | -18% | -1% | 2.8× | 32.2% | +7.1% |
| Adaptive Biotechnologies ADPT | United States | $4.47B | +103% | +50% | -12% | 14.7× | n/a | n/a |
| 10x Genomics TXG | United States | $7.72B | +174% | -4% | -14% | 11.8× | 41.8% | +16.6% |
| Twist Bioscience TWST | United States | $7.95B | +112% | +19% | -32% | 18.2× | n/a | n/a |